Geode Capital Management LLC raised its stake in shares of Ovid Therapeutics Inc (NASDAQ:OVID) by 7.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 95,865 shares of the company’s stock after purchasing an additional 6,391 shares during the period. Geode Capital Management LLC’s holdings in Ovid Therapeutics were worth $231,000 as of its most recent SEC filing.
A number of other hedge funds also recently added to or reduced their stakes in the business. Rhumbline Advisers boosted its stake in Ovid Therapeutics by 47.2% during the 4th quarter. Rhumbline Advisers now owns 16,551 shares of the company’s stock valued at $40,000 after purchasing an additional 5,310 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Ovid Therapeutics by 11.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 87,257 shares of the company’s stock valued at $211,000 after purchasing an additional 8,995 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Ovid Therapeutics during the 4th quarter valued at about $46,000. Institutional investors and hedge funds own 17.55% of the company’s stock.
Shares of NASDAQ OVID opened at $1.74 on Thursday. Ovid Therapeutics Inc has a twelve month low of $1.56 and a twelve month high of $11.45. The company has a market capitalization of $64.23 million, a PE ratio of -0.82 and a beta of 2.10. The company has a current ratio of 7.78, a quick ratio of 7.78 and a debt-to-equity ratio of 0.02.
A number of equities analysts have recently weighed in on OVID shares. Zacks Investment Research upgraded Ovid Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Saturday, March 9th. Piper Jaffray Companies cut their target price on Ovid Therapeutics to $14.00 and set an “overweight” rating on the stock in a research note on Sunday, March 10th. JMP Securities cut their target price on Ovid Therapeutics from $26.00 to $11.00 and set an “outperform” rating on the stock in a research note on Friday, March 8th. Finally, LADENBURG THALM/SH SH set a $27.00 target price on Ovid Therapeutics and gave the stock a “buy” rating in a research note on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $12.85.
In other Ovid Therapeutics news, CEO Jeremy M. Levin bought 75,000 shares of the business’s stock in a transaction dated Friday, February 22nd. The shares were purchased at an average price of $2.00 per share, for a total transaction of $150,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 43.90% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This piece of content was first published by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2019/05/16/geode-capital-management-llc-has-231000-holdings-in-ovid-therapeutics-inc-ovid.html.
Ovid Therapeutics Profile
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Featured Article: Benefits of owning preferred stock
Want to see what other hedge funds are holding OVID? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ovid Therapeutics Inc (NASDAQ:OVID).
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.